ACRO BIOMEDICAL CO., LTD.: 10-K/A filed 2018-01-16

Name: ACRO BIOMEDICAL CO., LTD.: 10-K/A filed 2018-01-16
Creator: ACRO BIOMEDICAL CO., LTD.

What ACRO BIOMEDICAL CO., LTD. reported in its annual report amendment filed 2018-01-16 (fiscal FY 2017): 20 published measures, 36 facts as tagged in accession 0001640334-18-000103.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form: 10-K/A (annual report amendment)
Filed: 2018-01-16
Fiscal period: fiscal FY 2017
Accession: 0001640334-18-000103 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACRO BIOMEDICAL CO., LTD. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-09-30	548,310	USD
At 2016-09-30	2,533	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-09-30	36,979	USD
At 2016-09-30	17,326	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2017-09-30	511,331	USD
At 2016-09-30	-14,793	USD
At 2015-09-30	28,635	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2017-09-30	36,810	USD
At 2016-09-30	2,533	USD
At 2015-09-30	27,275	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	-2,248	USD	365
2015-10-01 to 2016-09-30	-43,428	USD	366

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	510,000	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-09-30	-94,241	USD
At 2016-09-30	-91,993	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	0	USD	365
2015-10-01 to 2016-09-30	0	USD	366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-09-30	548,310	USD
At 2016-09-30	2,533	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-09-30	36,979	USD
At 2016-09-30	17,326	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	53,248	USD	365
2015-10-01 to 2016-09-30	43,428	USD	366

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2017-09-30	481,000	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	51,000	USD	365

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	459,000	USD	365

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	866	USD	365
2015-10-01 to 2016-09-30	1,055	USD	366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-09-30	47,660,000	shares
At 2016-09-30	47,160,000	shares

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2017-09-30	0	USD
At 2016-09-30	0	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	-2,248	USD	365
2015-10-01 to 2016-09-30	-43,428	USD	366

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	500,000	USD	365

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2016-10-01 to 2017-09-30	481,000	USD	365

Inspect the source

Entity: ACRO BIOMEDICAL CO., LTD. / CIK 0001622996
Captured: 2026-09-19T11:19:47.057Z
SEC response SHA-256: b3abbbd950a9b9c0ba03d5604cc52c43ddb41d59ea263147bca632d90b36b6c9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001622996.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))